UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Annals of oncology, 2022-08, Vol.33 (8), p.750-768

2022

Volltextzugriff (PDF)

Toxicity profiles of immunotherapy

Pharmacology & therapeutics (Oxford), 2018-01, Vol.181, p.91-100

2018

Volltextzugriff (PDF)

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Nature Medicine, 2022-06, Vol.28 (6), p.1199-1206

2022

Volltextzugriff (PDF)

WGS/WES-RNAseq compared to targeted NGS in oncology: is there something to unlock?

Annals of oncology, 2023-12, Vol.34 (12), p.1090-1093

2023

Volltextzugriff (PDF)

Role of perioperative chemotherapy in soft-tissue sarcomas: It's time to end a never-ending story

European journal of cancer (1990), 2018-07, Vol.97, p.53-54

2018

Volltextzugriff (PDF)

Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

Annals of oncology, 2016-06, Vol.27 (6), p.1178-1179

2016

Volltextzugriff (PDF)

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

European journal of cancer (1990), 2019-09, Vol.119, p.151-157

2019

Volltextzugriff (PDF)

Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer

Annals of oncology, 2022-10, Vol.33 (10), p.1084-1085

2022

Volltextzugriff (PDF)

Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment

Annals of oncology, 2017-12, Vol.28 (12), p.3108-3108

2017

Volltextzugriff (PDF)

Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key point

Annals of oncology, 2016-10, Vol.27 (10), p.1974-1975

2016

Volltextzugriff (PDF)

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Annals of oncology, 2021-11, Vol.32 (11), p.1381-1390

2021

Volltextzugriff (PDF)

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Annals of oncology, 2022-09, Vol.33 (9), p.909-915

2022

Volltextzugriff (PDF)

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Annals of oncology, 2022-10, Vol.33 (10), p.1041-1051

2022

Volltextzugriff (PDF)

Ancient bronze coins from Mediterranean basin: LAMQS potentiality for lead isotopes comparative analysis with former mineral

Applied surface science, 2016-11, Vol.387, p.529-538

2016

Volltextzugriff (PDF)

Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA

Annals of oncology, 2020-06, Vol.31 (6), p.822-823

2020

Volltextzugriff (PDF)

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas

Journal of hematology and oncology, 2021-12, Vol.14 (1), p.202-202, Article 202

2021

Volltextzugriff (PDF)

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

Annals of oncology, 2021-08, Vol.32 (8), p.1034-1044

2021

Volltextzugriff (PDF)

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma

Oncoimmunology, 2020-01, Vol.9 (1), p.1792036-1792036

2020

Volltextzugriff (PDF)

ESMO Recommendations on clinical reporting of genomic test results for solid cancers

Annals of oncology, 2024-07

2024

Volltextzugriff (PDF)

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

Scientific reports, 2019-10, Vol.9 (1), p.14551-8, Article 14551

2019

Volltextzugriff (PDF)

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

Cancer Immunology, Immunotherapy, 2022-12, Vol.71 (12), p.2985-2998

2022

Volltextzugriff (PDF)

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)

European journal of cancer (1990), 2020-01, Vol.125, p.31-37

2020

Volltextzugriff (PDF)

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

1 – 25 von 4.164

Suche als RSS-Feed

Aktive Filter

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.078)
Mit Volltextzugriff
(3.549)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.660)
Life Sciences & Biomedicine
(795)
Technology
(671)
Computer Science
(573)
Computer Science, Theory & Methods
(483)
Humans
(475)
Physical Sciences
(419)
Exact Sciences And Technology
(295)
Oncology
(278)
Applied Sciences
(246)
Computer Science; Control Theory; Systems
(232)
Theoretical Computing
(224)
Computer Science, Software Engineering
(156)
Mathematics
(154)
Hematology
(149)
Biological And Medical Sciences
(143)
Life Sciences
(141)
Italy
(134)
Engineering
(129)
Medical Sciences
(119)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Free E-Journals
(1.638)
IngentaConnect Journals
(1.591)
Journals@Ovid Full Text
(856)
Publisher or Other Site
(734)
Springer Book Series
(584)
MEDLINE
(566)
Elsevier ScienceDirect Journals Complete
(559)
Ebook Central Perpetual and DDA
(546)
IngentaConnect Journals
(448)
eBooks on EBSCOhost
(406)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(306)
Wiley-Blackwell Journals
(210)
Springer Journals
(210)
Wiley Online Library Full Collection 2018
(140)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(96)
IEEE Xplore
(67)
Nexis Uni
(61)
Oxford Journals
(57)
JSTOR
(53)
ACM Digital Library
(50)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Toxicity profiles of immunotherapy

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

WGS/WES-RNAseq compared to targeted NGS in oncology: is there something to unlock?

Role of perioperative chemotherapy in soft-tissue sarcomas: It's time to end a never-ending story

Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study

Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer

Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment

Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key point

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients

Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors

Ancient bronze coins from Mediterranean basin: LAMQS potentiality for lead isotopes comparative analysis with former mineral

Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma

ESMO Recommendations on clinical reporting of genomic test results for solid cancers

Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)

A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

Aktive Filter

Suchergebnisse filtern